Redmile Group’s Entrada Therapeutics TRDA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-560,971
| Closed | -$7.99M | – | 67 |
|
|
2024
Q2 | $7.99M | Sell |
560,971
-722,764
| -56% | -$10.3M | 0.48% | 42 |
|
|
2024
Q1 | $18.2M | Hold |
1,283,735
| – | – | 0.67% | 41 |
|
|
2023
Q4 | $19.4M | Sell |
1,283,735
-265
| -0% | -$4K | 0.69% | 39 |
|
|
2023
Q3 | $20.3M | Sell |
1,284,000
-27,572
| -2% | -$436K | 0.97% | 31 |
|
|
2023
Q2 | $19.9M | Sell |
1,311,572
-520,036
| -28% | -$7.87M | 0.76% | 39 |
|
|
2023
Q1 | $26.6M | Sell |
1,831,608
-22,500
| -1% | -$326K | 1.15% | 31 |
|
|
2022
Q4 | $25.1M | Sell |
1,854,108
-100,311
| -5% | -$1.36M | 1.03% | 29 |
|
|
2022
Q3 | $30.8M | Hold |
1,954,419
| – | – | 1.19% | 30 |
|
|
2022
Q2 | $23.8M | Hold |
1,954,419
| – | – | 0.91% | 32 |
|
|
2022
Q1 | $18.4M | Sell |
1,954,419
-1
| -0% | -$9 | 0.57% | 42 |
|
|
2021
Q4 | $33.5M | Buy |
+1,954,420
| New | +$33.5M | 0.76% | 37 |
|